Elevate Your Protein Production With SynWeave™: Save Up To 10 weeks With 4X Titer

As the demand for faster, more efficient biologics development continues to grow, innovative cell line development platforms are playing a critical role in improving productivity, manufacturability, and speed to clinic. In this webinar, Sunit Maity, Ph.D., Senior GM – Biologics Services at Syngene International Ltd., introduces SynWeave™, an advanced platform that combines state-of-the-art cell line and transposon-based technologies from ExcellGene with Syngene's integrated process development expertise.

By watching the presentation below, viewers will gain insight into the scientific foundation and evolution of the SynWeave™ platform, and learn how it is designed to accelerate cell line development timelines by up to 10 weeks while achieving titers of up to 10 g/L. The session also explores strategies for improving manufacturability through assured gene integration, robust clone selection, and enhanced cell line stability, helping to reduce development risk and support scalable production.

Designed to support a broad range of biologic modalities — including monoclonal antibodies, biosimilars, bispecific antibodies, ADCs, and other recombinant proteins — SynWeave™ offers a streamlined approach to delivering high-quality protein expression with greater efficiency.